Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...
Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.
Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...
TD Cowen Reaffirms Their Buy Rating on Enliven Therapeutics (ELVN)
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company’s ...
aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. Fourth positive DSMB review for efzofitimod in Phase 3 EFZO-FIT study reinforces ...
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.Fourth positive DSMB ...
University of Geneva15h
3 avril 2025: Pr Amin Rostami-Hodjegan
Pr Amin Rostami-Hodjegan 12H30 CMU - AUDITOIRE Müller (A250) suivi d'un apéritif. Hôtes: Pr Youssef Daali & Pr Pierre FONTANA Centre facultaire d’investigation ...